Literature DB >> 23983953

High-dose tricyclics potentiation with mirtazapine, lithium and partial sleep-deprivation: why not tricyclics in combination strategies for resistant melancholia?

Guadalupe Espárrago-Llorca, Laura Carrión-Expósito, Adela Hans-Chacón, Sergio Ruiz-Doblado.   

Abstract

Entities:  

Year:  2012        PMID： 23983953      PMCID： PMC3736928          DOI： 10.1177/2045125311428504

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN： 2045-1253


× No keyword cloud information.
  6 in total

1.  Venlafaxine plus mirtazapine as first-line treatment for melancholia: preliminary results.

Authors:  Sergio Ruiz-Doblado; Teresa Rueda-Villar; Pilar Zurita-Gotor; Sebastian Sanz-Cortes
Journal:  J Psychopharmacol       Date:  2010-12       Impact factor: 4.153

Review 2.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

3.  Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.

Authors:  Noel Hannan; Zaf Hamzah; Henry Omoniyi Akinpeloye; David Meagher
Journal:  J Psychopharmacol       Date:  2007-03       Impact factor: 4.153

4.  Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?

Authors:  Nicola Gervasoni; Jean-Michel Aubry; Marianne Gex-Fabry; Gilles Bertschy; Guido Bondolfi
Journal:  Pharmacol Res       Date:  2008-11-27       Impact factor: 7.658

5.  Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

Authors:  Pierre Blier; Herbert E Ward; Philippe Tremblay; Louise Laberge; Chantal Hébert; Richard Bergeron
Journal:  Am J Psychiatry       Date:  2009-12-15       Impact factor: 18.112

Review 6.  Which antidepressants have demonstrated superior efficacy? A review of the evidence.

Authors:  Stuart A Montgomery; David S Baldwin; Pierre Blier; Naomi A Fineberg; Siegfried Kasper; Malcolm Lader; Raymond W Lam; Jean-Pierre Lépine; Hans-Jürgen Möller; David J Nutt; Frederic Rouillon; Alan F Schatzberg; Michael E Thase
Journal:  Int Clin Psychopharmacol       Date:  2007-11       Impact factor: 1.659
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.